Innoviva (INVA) closed at $21.06 on October 22, 2026, up 0.7% from the previous close, on volume of 434,084 shares (30-day average 878,083).
Data as of October 22, 2026.
22-Oct-2026
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Business Wire (Mon, 19-Oct 8:00 AM ET)
Innoviva to Participate in Upcoming Investor Conferences
Business Wire (Wed, 2-Sep 8:00 AM ET)
Business Wire (Tue, 11-Aug 4:05 PM ET)
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Business Wire (Wed, 5-Aug 4:05 PM ET)
Innoviva’s Zoliflodacin Phase 3 Results Signal a Turning Point in Gonorrhea Treatment
Market Chameleon (Fri, 12-Dec 2:31 AM ET)
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Innoviva trades on the NASDAQ stock market under the symbol INVA.
As of October 22, 2026, INVA stock price climbed to $21.06 with 434,084 million shares trading.
INVA has a beta of -0.14, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.00 to the broad based SPY ETF.
INVA has a market cap of $1.52 billion. This is considered a Small Cap stock.
Last quarter Innoviva reported $120 million in Revenue and -$1.14 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$1.65.
In the last 3 years, INVA traded as high as $25.15 and as low as $12.22.
The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, IWM, VB, DFSV.
INVA has underperformed the market in the last year with a return of +14.8%, while the SPY ETF gained +15.5%. In the last 3 month period, INVA fell short of the market, returning -1.7%, while SPY returned +2.5%. However, in the most recent 2 weeks INVA has outperformed the stock market by returning +0.9%, while SPY returned -1.3%.
INVA support price is $20.54 and resistance is $21.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.
